|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||75.87 - 76.76|
|52-week range||71.72 - 87.80|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||27.49|
|Earnings date||29 Apr 2021|
|Forward dividend & yield||2.60 (3.41%)|
|Ex-dividend date||12 Mar 2021|
|1y target est||95.81|
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Dr. Shereef Elnahal, University Hospital CEO, Former NJDOH Commissioner, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on coronavirus vaccines.
Merck (MRK) is developing a Keytruda monotherapy regimen for adjuvant treatment of renal cell carcinoma patients.